A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

Condition:   Norovirus Infections Intervention:   Biological: VXA-G1.1-NN Sponsor:   Vaxart Recruiting

Source: ClinicalTrials.gov - January 28, 2022 Category: Research Source Type: clinical trials